Navigation Links
Pier Pharmaceuticals Names Peter Letendre as Chief Executive Officer, President and Director
Date:12/17/2010

nsible for in his career eclipsed $1 Billion in sales.  Pete is also the co-founder of LiquiForm Pharmaceuticals and Calor Therapeutics. In addition to his broad-based experience in the pharmaceutical industry, Pete also enjoyed a distinguished career as a clinician, academician, researcher and educator prior to entering the pharmaceutical industry in 1990.  Pete holds a Bachelor of Science (BS) degree in pharmacy and a Doctor of Pharmacy degree (Pharm.D.) both from the Massachusetts College of Pharmacy and Allied Health Sciences.

"I am thrilled to be given the opportunity to lead Pier Pharmaceuticals as we further develop our lead asset for the treatment of obstructive sleep apnea, a medical condition estimated to occur in 18-20 million Americans.  OSA is associated with significant morbidity for which there is no currently approved pharmacologic option" said Dr. Letendre. "I strongly believe that an effective pharmacologic option for treating OSA will be an exceedingly important addition to the armamentarium of practicing physicians faced with managing this complex syndrome on a daily basis."

About Pier Pharmaceuticals

Pier Pharmaceuticals (formerly known as Steady Sleep Rx Co.) is a venture-backed clinical stage biopharmaceutical company founded in 2007 which is focused on the development and commercialization of products to treat sleep related breathing disorders, notably obstructive sleep apnea with its lead compound in development, PP-001. Institutional investors include IllinoisVENTURES and Origin Ventures. For more information about the company, its management and Board of Directors, please visit www.pierpharmaceuticals.com.


'/>"/>
SOURCE Pier Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
3. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
4. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
5. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
6. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
7. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
8. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
9. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
10. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
11. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... April 1, 2015  Spherix Incorporated (Nasdaq: ... the fostering and monetization of intellectual property, today ... held full service global investment bank specializing in ... industry note featuring Spherix. The report, ... Senior Analyst at Chardan, was published on March ...
(Date:4/1/2015)... 2015 Immunocore Limited ("the ... drugs to treat cancer, viral infections and autoimmune ... of Christina Coughlin as Chief Medical ... medical and regulatory leadership to the pre-clinical and ... Coughlin has extensive experience in oncology drug development, ...
(Date:3/31/2015)... March 31, 2015 Materials in ... ,   June 30 2015   Elsevier ... products and services and publishing home of Materials Today ... launched the Materials in Society  Lecture Series ... 8 th International Conference on Materials for Advanced ...
(Date:3/31/2015)... March 31, 2015  The Myeloma Crowd Research Initiative ... of ten proposals that will now be evaluated ... patient-led, scientifically validated funding initiative uncovering solutions for ... of the MCRI included preliminary vetting by the ... large number of innovative projects focusing on high-risk ...
Breaking Biology Technology:Chardan Capital Issues Industry Note Covering Spherix 2Chardan Capital Issues Industry Note Covering Spherix 3Immunocore Appoints Dr. Christina Coughlin as Chief Medical Officer 2Immunocore Appoints Dr. Christina Coughlin as Chief Medical Officer 3Immunocore Appoints Dr. Christina Coughlin as Chief Medical Officer 4Elsevier Materials Science Council Introduces the Materials in Society Lecture Series at the International Conference on Materials for Advanced Technologies (ICMAT) 2Elsevier Materials Science Council Introduces the Materials in Society Lecture Series at the International Conference on Materials for Advanced Technologies (ICMAT) 3Myeloma Crowd Research Initiative Selects 10 High-Risk Multiple Myeloma Proposals For Further Review 2
... , , SAN DIEGO, ... announced its financial results for the quarter ended June 30, 2009. For ... $15.3 million, or $0.39 per share, compared with a net loss of ... For the six months ended June 30, 2009, the Company reported a ...
... Group, Inc. ("BioNeutral") (OTC Bulletin Board: BONU), a chemical technology-based Life Science ... Kielbania will appear on WVOX AM,s "In Focus" radio show on Wednesday ... The radio broadcast may be accessed via the Internet at ... Dan Miller , Dr. Miller is a retired school and college ...
... , , SOUTH SAN ... ) today reported financial results for the second quarter ended June 30, ... of 2009 was $3.5 million, with a net loss of $22.9 million, ... April. Loss from operations was $1.9 million for the second quarter and ...
Cached Biology Technology:Neurocrine Biosciences Reports Second Quarter 2009 Results 2Neurocrine Biosciences Reports Second Quarter 2009 Results 3Neurocrine Biosciences Reports Second Quarter 2009 Results 4Neurocrine Biosciences Reports Second Quarter 2009 Results 5Neurocrine Biosciences Reports Second Quarter 2009 Results 6Neurocrine Biosciences Reports Second Quarter 2009 Results 7BioNeutral Group's CEO, Stephen Browand and Chief Scientist, Dr. Andrew Kielbania to Appear on WVOX 1460 AM 'In Focus' Radio Show Hosted by Dr. Dan Miller 2Sunesis Reports Financial Results for the Second Quarter 2009 2Sunesis Reports Financial Results for the Second Quarter 2009 3Sunesis Reports Financial Results for the Second Quarter 2009 4Sunesis Reports Financial Results for the Second Quarter 2009 5Sunesis Reports Financial Results for the Second Quarter 2009 6Sunesis Reports Financial Results for the Second Quarter 2009 7Sunesis Reports Financial Results for the Second Quarter 2009 8Sunesis Reports Financial Results for the Second Quarter 2009 9Sunesis Reports Financial Results for the Second Quarter 2009 10Sunesis Reports Financial Results for the Second Quarter 2009 11
(Date:3/17/2015)... NEW YORK , March 17, 2015 /PRNewswire/ ... , the largest exhibition for service robots ever ... . RoboUniverse takes place on May 11-13, 2015 ... Sponsors and exhibitors for the event include: Acorn ... Motion Control; EZ-Robot; Infranor; Kinova Robotics; Littler; NewBotic ...
(Date:3/12/2015)... IriTech, a leading iris based identity management ... Instruments Design Network, announced today that the Chief Minister ... USB MK2120U device during a launching event of Andhra ... The iris scanner is manufactured by U.S. ... India through its Indian partner, Biometronic ...
(Date:3/12/2015)... 2015 Beta Systems today ... access management (IAM) solution for a fixed price ... System,s new IAM package, customers benefit from the ... multiple IAM implementations across different industries. The new ... as any necessary services and consulting. It spans ...
Breaking Biology News(10 mins):MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 3Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2
... people usually don,t die from a heart attack. But the ... succumb to congestive heart failure, the most common cause of ... hope for achieving what the body can,t do: mending broken ... built a scaffold that supports the growth and integration of ...
... -- A microscopic gene may play a gigantic role when ... to one Kansas State University research team. The team ... Disintegrin and Metalloprotease family, or ADAM family, and its role ... is a good guy or a bad guy in breast ...
... against cancerous tumors, radiation therapy often harms healthy tissue as ... of Tel Aviv University,s Department of Biomedical Engineering is developing ... and minimal damage to surrounding tissue. His innovative ... uses heat to kill the tumor cells but leaves ...
Cached Biology News:A strategy to fix a broken heart 2A strategy to fix a broken heart 3K-State research team investigates mutated gene's role in breast cancer 2A 'magnetic' solution to identify and kill tumors 2
The FlowTACS Apoptosis Detection Kit is designed specifically for in situdetection of apoptotic...
RayBio Human Cytokine Antibody Array 1.1 (4 array membranes) with Accessory, detects 20 cytokines (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
HybriWell™ hybridization sealing system, 22 mm x 22 mm chamber, 0.15 mm deep *set of 100*...
RABBIT ANTI ISOCITRATE DEHYDROGENASE...
Biology Products: